Acuta Capital Partners LLC Has $10.35 Million Stock Position in Ocular Therapeutix, Inc. (NASDAQ:OCUL)

Acuta Capital Partners LLC trimmed its position in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) by 57.1% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,190,071 shares of the biopharmaceutical company’s stock after selling 1,581,059 shares during the quarter. Ocular Therapeutix makes up 8.4% of Acuta Capital Partners LLC’s holdings, making the stock its 2nd biggest holding. Acuta Capital Partners LLC’s holdings in Ocular Therapeutix were worth $10,354,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Atlas Capital Advisors LLC acquired a new stake in Ocular Therapeutix in the second quarter valued at $34,000. Amalgamated Bank increased its stake in shares of Ocular Therapeutix by 37.9% in the second quarter. Amalgamated Bank now owns 5,384 shares of the biopharmaceutical company’s stock valued at $37,000 after buying an additional 1,481 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Ocular Therapeutix by 22.0% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,639 shares of the biopharmaceutical company’s stock valued at $49,000 after buying an additional 1,015 shares during the period. Algert Global LLC bought a new position in shares of Ocular Therapeutix during the second quarter worth about $69,000. Finally, Capital Performance Advisors LLP acquired a new position in shares of Ocular Therapeutix in the third quarter worth approximately $70,000. 59.21% of the stock is currently owned by institutional investors.

Ocular Therapeutix Stock Performance

Shares of Ocular Therapeutix stock opened at $10.06 on Thursday. The business has a 50-day simple moving average of $9.94 and a 200 day simple moving average of $8.21. The firm has a market capitalization of $1.58 billion, a price-to-earnings ratio of -7.62 and a beta of 1.26. The company has a debt-to-equity ratio of 0.19, a current ratio of 13.01 and a quick ratio of 12.94. Ocular Therapeutix, Inc. has a one year low of $2.16 and a one year high of $11.77.

Insider Activity

In related news, insider Jeffrey S. Heier sold 2,948 shares of Ocular Therapeutix stock in a transaction on Monday, November 25th. The shares were sold at an average price of $9.01, for a total value of $26,561.48. Following the completion of the sale, the insider now owns 269,059 shares of the company’s stock, valued at approximately $2,424,221.59. This trade represents a 1.08 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Corporate insiders own 3.50% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on OCUL shares. Scotiabank began coverage on shares of Ocular Therapeutix in a research report on Wednesday, October 16th. They set a “sector outperform” rating and a $22.00 target price for the company. Robert W. Baird lowered their target price on shares of Ocular Therapeutix from $18.00 to $17.00 and set an “outperform” rating for the company in a research note on Thursday, August 8th. Finally, HC Wainwright boosted their target price on shares of Ocular Therapeutix from $14.00 to $15.00 and gave the company a “buy” rating in a report on Friday, November 15th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and six have given a buy rating to the company. According to MarketBeat, Ocular Therapeutix currently has a consensus rating of “Moderate Buy” and an average price target of $16.71.

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.